Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(02): 210-214
DOI: 10.4103/ijmpo.ijmpo_133_17
Original Article

KRAS and NRAS Testing in Metastatic Colorectal Cancer in Central Iran (Tehran): A Review on Literature of the Middle East

Ali Shahriari-Ahmadi
Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
,
Nafise Ansarinejad
Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
,
Farshid Fardad
Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
,
Mehrdad Abbaszadeh
Department of Hematology and Medical Oncology, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
,
Masoud Sadeghi
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Context: The incidence of colorectal cancer (CRC) in the past three decades in Iran has made it as a major public health burden. Aims: The aim of this study is to report the prevalence of KRAS and NRAS mutations in Iran and the correlation between KRAS mutation status with clinicopathological factors and survival.Materials and Methods: In a cross-sectional study, 144 patients were entered into the study based on the criteria. Age, sex, tumor site, grade, metastasis location, familial history, KRAS/NRAS status, and survival were checked for all patients, and the patients were followed for 1 year. DNA was extracted with FFPE QIAGEN kit and then polymerase chain reaction for amplification of gene segments of KRAS and NRAS genes. Results: The mean age at diagnosis was 52.9 years (range: 27–72 years) that 39.6% patients had age <50 years and 54.2% were men. KRAS mutation was significantly more in the patients with age ≥50 compared with KRAS wild type. Furthermore, the 6-month overall survival rate in KRAS mutation patients was significantly more than KRAS wild-type patients. Liver metastasis (72.9%) had the highest prevalence of metastasis in the patients, and Grade II with 64.6% had the most prevalence. Conclusions: The metastatic CRC was more prevalent in men than women, and the mean age varied around 50–60 years. The results showed that the present study had the highest prevalence of KRAS mutation in the Middle East and Pakistan with the lowest prevalence in CRC patients.

Keywords

Colorectal cancer - Iran - KRAS - NRAS


Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev 2015; 16: 7603-6
    CrossrefPubMedGoogle Scholar
  • 2 Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi KermaniI, Farassati F, Dastgiri S. et al. Colorectal cancer in Iran: Molecular epidemiology and screening strategies. J Cancer Epidemiol 2015; 2015: 643020
    CrossrefPubMedGoogle Scholar
  • 3 Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol 2015; 21: 11767-76
    CrossrefPubMedGoogle Scholar
  • 4 Payandeh M, Sadeghi M, Sadeghi E. The report of KRAS mutation and NRAS wild type in a patient with thyroid metastasis from colon cancer: A Rare case report. Iran J Pathol 2016; 11: 71-5
    PubMedGoogle Scholar
  • 5 Van CutsemE, Oliveira J. ESMO Guidelines Working Group. et al. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 61-3
    CrossrefPubMedGoogle Scholar
  • 6 Bajpai J, Susan D, Patil V, Nair R, Ghosh J, Badwe RA. et al. Taxane combination chemotherapy in breast cancer: Experience from a tertiary cancer centre in India. Indian J Med Paediatr Oncol 2017; 38: 18-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Payandeh M, Sadeghi M, Sadeghi E, Gholami F. Analysis of KRAS, BRAF and NRAS in patients with colorectal cancer: The first report of Western Iran. Am J Cancer Prev 2015; 3: 19-22
    Google Scholar
  • 8 Geramizadeh b. Molecular biomarkers of colorectal cancer: A review of published articles from Iran. Ann Colorectal Res 2015; 3: e30100
    CrossrefGoogle Scholar
  • 9 Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D. et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19: 157-63
    CrossrefPubMedGoogle Scholar
  • 10 Payandeh M, Shazad B, Sadeghi M, Shahbazi M. Correlation between RAS test results and prognosis of metastatic colorectal cancer patients: A Report from Western Iran. Asian Pac J Cancer Prev 2016; 17: 1729-32
    CrossrefPubMedGoogle Scholar
  • 11 Amirifard N, Sadeghi E, Farshchian N, Haghparast A, Choubsaz M. Evaluation of KRAS gene mutations in metastatic colorectal cancer patients in Kermanshah province. Asian Pac J Cancer Prev 2016; 17: 3085-8
    PubMedGoogle Scholar
  • 12 Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M. et al. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico Dell'italia Meridionale study): Influence of microsatellite instability status and country of origin. Ann Oncol 2006; 17 Suppl 7: vii91-6
    CrossrefPubMedGoogle Scholar
  • 13 Koochak A, Rakhshani N, Karbalaie NiyaMH, Tameshkel FS, Sohrabi MR, Babaee MR. et al. Mutation analysis of KRAS and BRAF genes in metastatic colorectal cancer: A First large scale study from Iran. Asian Pac J Cancer Prev 2016; 17: 603-8
    CrossrefPubMedGoogle Scholar
  • 14 Omidifar NMd, Geramizadeh GMd, Mirzai MMs. K-ras mutation in colorectal cancer, A report from Southern Iran. Iran J Med Sci 2015; 40: 454-60
    PubMedGoogle Scholar
  • 15 Mohsen A, Ahmadreza S, Fatemeh H, Fatemeh H, Fariba ER. et al. Frequency of K-RAS and N-RAS gene mutations in colorectal cancers in Southeastern Iran. Asian Pac J Cancer Prev 2016; 17: 4511-5
    PubMedGoogle Scholar
  • 16 Bader T, Ismail A. Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. Alexandria J Med 2014; 50: 203-9
    CrossrefGoogle Scholar
  • 17 Zekri J, Al-Shehri A, Mahrous M, Al-Rehaily S, Darwish T, Bassi S. et al. Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: Frequency, clincopathological associations, and clinical outcomes. Genet Mol Res 2017; 16: 1-11
    CrossrefPubMedGoogle Scholar
  • 18 Gorukmez O, Yakut T, Gorukmez O, Sag SO, Karkucak M, Kanat O. et al. Distribution of KRAS and BRAF mutations in metastatic colorectal cancers in Turkish patients. Asian Pac J Cancer Prev 2016; 17: 1175-9
    CrossrefPubMedGoogle Scholar
  • 19 Selcukbiricik F, Erdamar S, Ozkurt CU, Molinas MandelN, Demirelli F, Ozguroglu M. et al. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON 2013; 18: 116-23
    PubMedGoogle Scholar
  • 20 Ozen F, Ozdemir S, Zemheri E, Hacimuto G, Silan F, Ozdemir O. et al. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genet Test Mol Biomarkers 2013; 17: 135-9
    CrossrefPubMedGoogle Scholar
  • 21 Murtaza BN, Bibi A, Rashid MU, Khan YI, Chaudri MS, Shakoori AR. et al. Spectrum of K ras mutations in Pakistani colorectal cancer patients. Braz J Med Biol Res 2014; 47: 35-41
    CrossrefPubMedGoogle Scholar
  • 22 Elsabah MT, Adel I. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst 2013; 25: 51-6
    CrossrefPubMedGoogle Scholar
  • 23 Kumar S, Burney IA, Zahid KF, DSouza PC, Belushi MA, Mufti TD. et al. Colorectal cancer patient characteristics, treatment and survival in Oman – A single center study. Asian Pac J Cancer Prev 2015; 16: 4853-8
    CrossrefPubMedGoogle Scholar
  • 24 Al-Allawi NA, Ismaeel AT, Ahmed NY, Merza NS. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma. Indian J Cancer 2012; 49: 163-8
    CrossrefPubMedGoogle Scholar